Actavis, a global leader in the generic pharmaceuticals industry, yesterday announced it has entered into a binding letter of intent with QRxPharma to launch MoxDuo® IR in the United States.  Read the full story

Leading generic pharmaceuticals company Actavis recently sent 170 pallets of medicine from Malta to Tripoli, Libya to aid civilians in the crisis. Read the full story

Leading generic pharmaceutical company Actavis recently announced it will be extending its backing of the drug prevention programme, Youth in Europe (YIE) until 2016. Read the full story

The generic pharmaceuticals company, Actavis Group, this week marketed Olanzapine tablets across several European countries immediately after the patents expired on September 26^th and 27^th, respectively. Read the full story

According to German media, the Icelandic generic company, Actavis is currently planning its expansion through future acquisitions. CEO at Actavis, Claudio Albrecht is reported to have said “we [Actavis] want to grow in the coming years by an average of ten to twelve percent – faster than the current growth of the market itself.” Read the full story

Actavis Group, the international generic pharmaceuticals company headquartered in Iceland, yesterday announced it has successfully agreed a debt refinancing in collaboration with its lenders. Read the full story

Actavis Group, the international generic pharmaceuticals company, today announced the appointment of former Ratiopharm leader Dr. Claudio Albrecht as its new CEO.

Read the full story

The product, Atorvastatin Magnesium, has been launched by four of Spain’s largest generic pharmaceutical companies. Actavis recently announced that its third-party sales division, Medis, has delivered around 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market and distribution to Spanish pharmacies has already commenced. Read the full story

Actavis has decided to give Icelandic health institutions a gift by offering the company’s first hypodermic cancer drugs on the Icelandic market for free. A year’s supply of five different drugs is being made available to Icelandic health institutions without charge: four from 1st April 2009 and one from 1st January 2010. Read the full story

Actavis Group and Japan’s ASKA Pharmaceutical have formally signed an agreement establishing a joint company: Actavis ASKA K.K. with its head office in Tokyo. The preliminary agreement was signed last November. Read the full story